Ferreira Arlindo, Alho Irina, Casimiro Sandra, Costa Luís
Hospital de Santa Maria , Lisbon, Portugal ; Instituto de Medicina Molecular, Faculdade de Medicina , Universidade de Lisboa, Lisbon, Portugal.
Instituto de Medicina Molecular, Faculdade de Medicina , Universidade de Lisboa, Lisbon, Portugal.
Bonekey Rep. 2015 Apr 22;4:668. doi: 10.1038/bonekey.2015.35. eCollection 2015.
Bone metastasis is a frequent finding in the natural history of several types of cancers. However, its anticipated risk, diagnosis and response to therapy are still challenging to assess in clinical practice. Markers of bone metabolism are biochemical by-products that provide insight into the tumor-bone interaction, with potential to enhance the clinical management of patients with bone metastases. In fact, these markers had a cornerstone role in the development of bone-targeted agents; however, its translation to routine practice is still unclear, as reflected by current international guidelines. In this review, we aimed to capture several of the research and clinical translational challenges regarding the use of bone metabolism markers that we consider relevant for future research in bone metastasis.
骨转移是多种癌症自然病程中的常见表现。然而,在临床实践中,对其预期风险、诊断及治疗反应进行评估仍具有挑战性。骨代谢标志物是生化副产物,可深入了解肿瘤与骨的相互作用,有望改善骨转移患者的临床管理。事实上,这些标志物在骨靶向药物的研发中发挥了关键作用;然而,正如当前国际指南所反映的,其在常规实践中的应用仍不明确。在本综述中,我们旨在梳理一些与骨代谢标志物使用相关的研究及临床转化挑战,我们认为这些挑战对未来骨转移研究具有重要意义。